The results of these trials have consistently demonstrated the cardiovascular benefits associated with GLP-1 receptor agonists including reductions in major adverse cardiovascular events. These findings have provided valuable insights into the management of T2D and informed clinical practice ...
- Research has found that people taking GLP-1 medications to treat diabetes, overweight, or obesity have fewer major cardiovascular events, like heart attack or stroke, compared to people not taking GLP-1 medications.
Moving forward, it's essential to keep these visual contexts in mind when discussing Glp-1 Medication And Cardiovascular Disease.
- This new data tells us that GLP-1s may be beneficial in reducing the burden of heart disease regardless of background or income. Related reading: Research Identifies Gapsand Opportunitiesin Heart Disease Care Among Older Women.
Moving forward, it's essential to keep these visual contexts in mind when discussing Glp-1 Medication And Cardiovascular Disease.
- The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment.
Compared with sitagliptin, a diabetes drug that has shown neutral effects on cardiovascular outcomes, semaglutide reduced the risk of stroke and heart attack by 18 percent. Treatment with tirzepatide lowered the risk of stroke, heart attack, and death by 13 percent compared to dulaglutide, another GLP-1 receptor agonist that has been available for many years.
- These advances have prompted the American Diabetes Association (ADA), American Association of Clinical Endocrinology (AACE), and other professional societies to update clinical practice guidelines and recommend use of these agents in patients with diabetes mellitus (DM) and established cardiovascular disease (CVD) regardless of hemoglobin A1c concentrations, including consideration as first-line pharmacotherapy. Specific formulations of GLP1RAs are indicated (semaglutide as Wegovy and liraglutide as Saxenda [Novo Nordisk Inc., Bagsvaerd, Denmark]) or used off-label (semaglutide as Ozempic [Novo Nordisk Inc., Bagsvaerd, Denmark] and tirzepatide as Mounjaro [Lilly USA LLC, Indianapolis, Indiana]) for chronic weight management as an adjunct to lifestyle changes.
Their role in preventing heart ... are currently under investigation. Studies completed to date show that they do not increase the risk of cardiovascular disease when compared to placebo....
